Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil antagonism of remimazolam in kidney transplant
NCT06531369Phase 1Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Allosteric Modulators
01
Overview
Phase 1, randomised, double-blind trial of flumazenil in general anesthesia (3 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Plasma Concentration of Remimazolam. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
flumazenil
03
Conditions
general anesthesia
Beyond the preview
Go deeper on NCT06531369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531369.